Correlation Between Takeda Pharmaceutical and Swedish Orphan
Can any of the company-specific risk be diversified away by investing in both Takeda Pharmaceutical and Swedish Orphan at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Takeda Pharmaceutical and Swedish Orphan into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Takeda Pharmaceutical and Swedish Orphan Biovitrum, you can compare the effects of market volatilities on Takeda Pharmaceutical and Swedish Orphan and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Takeda Pharmaceutical with a short position of Swedish Orphan. Check out your portfolio center. Please also check ongoing floating volatility patterns of Takeda Pharmaceutical and Swedish Orphan.
Diversification Opportunities for Takeda Pharmaceutical and Swedish Orphan
-0.18 | Correlation Coefficient |
Good diversification
The 3 months correlation between Takeda and Swedish is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Takeda Pharmaceutical and Swedish Orphan Biovitrum in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Swedish Orphan Biovitrum and Takeda Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Takeda Pharmaceutical are associated (or correlated) with Swedish Orphan. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Swedish Orphan Biovitrum has no effect on the direction of Takeda Pharmaceutical i.e., Takeda Pharmaceutical and Swedish Orphan go up and down completely randomly.
Pair Corralation between Takeda Pharmaceutical and Swedish Orphan
Assuming the 90 days horizon Takeda Pharmaceutical is expected to under-perform the Swedish Orphan. But the stock apears to be less risky and, when comparing its historical volatility, Takeda Pharmaceutical is 1.51 times less risky than Swedish Orphan. The stock trades about -0.02 of its potential returns per unit of risk. The Swedish Orphan Biovitrum is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest 1,917 in Swedish Orphan Biovitrum on September 26, 2024 and sell it today you would earn a total of 769.00 from holding Swedish Orphan Biovitrum or generate 40.11% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Takeda Pharmaceutical vs. Swedish Orphan Biovitrum
Performance |
| Timeline |
| Takeda Pharmaceutical |
| Swedish Orphan Biovitrum |
Takeda Pharmaceutical and Swedish Orphan Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Takeda Pharmaceutical and Swedish Orphan
The main advantage of trading using opposite Takeda Pharmaceutical and Swedish Orphan positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Takeda Pharmaceutical position performs unexpectedly, Swedish Orphan can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Swedish Orphan will offset losses from the drop in Swedish Orphan's long position.| Takeda Pharmaceutical vs. Zoetis Inc | Takeda Pharmaceutical vs. Eisai Co | Takeda Pharmaceutical vs. Catalent | Takeda Pharmaceutical vs. Teva Pharmaceutical Industries |
| Swedish Orphan vs. Zoetis Inc | Swedish Orphan vs. Takeda Pharmaceutical | Swedish Orphan vs. Eisai Co | Swedish Orphan vs. Catalent |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Complementary Tools
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |